Meet the Expert - Judd W. Moul

Tweet

Judd W. Moul, MD
Director, Duke Prostate Center
James H. Semans, MD, Professor of Surgery

Judd W. Moul, MD graduated summa cum laude from Pennsylvania State University. He earned his degree from Jefferson Medical College, where he was elected to Phi Beta Kappa and Alpha Omega Alpha. He completed his Urologic-Oncology Fellowship at Duke.

He has received grants from the National Institutes of Health, DoD, Veterans Affairs and CaPCURE Foundation, and has managed the cumulative $50 million in grants from the U.S. Army Medical Research and Materiel Command since the inception of Center for Prostate Disease Research in 1992. Moul has authored and co-authored more than 275 scientific manuscripts and book chapters, including articles in the New England Journal of Medicine and the Journal of the American Medical Association.

Honors received include the 1995 American Medical Association Young Physicians Section Community Service Award for his national involvement in prostate cancer patient support groups, the 1996 Sir Henry Welcome Research Medal and Prize from the Association of Military Surgeons of the United States, and selection as a 1994 Fellow for the American Urological Association/European Association of Urology International Academic Exchange Program. In 1997, Moul was the recipient of the Gold Cystoscope Award from the American Urological Association. He received the Baron Dominique Jean Larrey Military Surgeon Award for Excellence in 1998 and the Presidential Award from the Uniformed Services Urology Research Group in 2000.

Moul is on the editorial board of several medical journals, including Oncology, Journal of Urology, Urology, and the periodical Oncology News International. He is also co-editor of the journal, Prostate Cancer and Prostatic Diseases, and is medical editor for Family Urology, a patient education magazine published by the American Foundation for Urologic Disease.

He is nationally recognized for his creation of a U.S. military-based prostate disease research database that houses information on more than 20,000 prostate cancer patients treated at nine collaborating institutions.

At the AUA 2012

• mCRPC in focus: Androgen biosynthesis inhibition and metastatic castration-resistant prostate cancer, clinical insights from the Clinical Industry Theater presentation
• Understanding and sequencing abiraterone acetate in patients with metastatic castration-resistant prostate cancer - Exclusive Podcast 
• Androgen biosynthesis inhibition and metastatic castration-resistant prostate cancer - Exclusive Interview 
• Does long-term aspirin use lower serum PSA levels? – Results from the Duke Prostate Center - Session Highlights 
• Unilateral prostate cancer: Analysis of predictors in search and Duke Prostate Center databases - Session Highlights

Recent Representative Publications

• Caire AA, Sun L, Lack BD, Lum K, Tang P, Stackhouse DA, Robertson CN, Mouraviev V, Polascik TJ, Albala DM, Moul JW. Predicting non-organ-confined prostate cancer in men diagnosed after 2000. Prostate Cancer Prostatic Dis. 2010 Sep;13(3):248-51. (2010)
• Caire AA, Sun L, Polascik TJ, Albala DM, Moul JW. Obese African-Americans with prostate cancer (T1c and a prostate-specific antigen, PSA, level of <10 ng/mL) have higher-risk pathological features and a greater risk of PSA recurrence than non-African-Americans. BJU Int. 2010 Mar 29. (2010)
• Caso JR, Mouraviev V, Tsivian M, Polascik TJ, Moul JW. Prostate cancer: an evolving paradigm. J Endourol. 2010 May;24(5):805-9. (2010)
• Caso JR, Tsivian M, Mouraviev V, Polascik TJ, Moul JW. Pathological T2 sub-divisions as a prognostic factor in the biochemical recurrence of prostate cancer. BJU Int. 2010 Jun 14. (2010)
• D'Amico AV, Chen MH, Sun L, Lee WR, Mouraviev V, Robertson CN, Walther PJ, Polascik TJ, Albala DM, Moul JW. Adjuvant versus salvage radiation therapy for prostate cancer and the risk of death. BJU Int. 2010 Jun 14. (2010)
• Droz JP, Balducci L, Bolla M, Emberton M, Fitzpatrick JM, Joniau S, Kattan MW, Monfardini S, Moul JW, Naeim A, van Poppel H, Saad F, Sternberg CN. Management of prostate cancer in older men: recommendations of a working group of the International Society of Geriatric Oncology. BJU Int. 2010 Aug;106(4):462-9. (2010)
• Moreira DM, Presti JC Jr, Aronson WJ, Terris MK, Kane CJ, Amling CL, Sun LL, Moul JW, Freedland SJ. The effect of race on the discriminatory accuracy of models to predict biochemical recurrence after radical prostatectomy: results from the Shared Equal Access Regional Cancer Hospital and Duke Prostate Center databases. Prostate Cancer Prostatic Dis. 2010 Mar;13(1):87-93. (2010)
• Moul JW. Radiotherapy: Secondary malignancies after prostate cancer treatment. Nat Rev Clin Oncol. 2010 May;7(5):249-50. (2010)
• Schroeck FR, Kattan MW, Moul JW, Aronson WJ, Presti JC Jr, Terris MK, Kane CJ, Amling CL, Sun L, Freedland SJ. Re-calibration and external validation of an existing nomogram to predict aggressive recurrences after radical prostatectomy. BJU Int. 2010 Jun;105(12):1654-9. (2010)
• Tang P, Sun L, Uhlman MA, Polascik TJ, Freedland SJ, Moul JW. Baseline PSA as a predictor of prostate cancer-specific mortality over the past 2 decades: duke university experience. Cancer. 2010 Jun 29. (2010)
• Tang P, Sun L, Uhlman MA, Robertson CN, Polascik TJ, Albala DM, Donatucci CF, Moul JW. Initial prostate specific antigen 1.5 ng/ml or greater in men 50 years old or younger predicts higher prostate cancer risk. J Urol. 2010 Mar;183(3):946-50. (2010)
• Tsivian M, Moreira DM, Sun L, Mouraviev V, Kimura M, Moul JW, Polascik TJ. Biopsy accuracy in identifying unilateral prostate cancer depends on prostate weight. Urol Oncol. 2010 Jan 5. (2010)
• Uhlman MA, Sun L, Stackhouse DA, Polascik TJ, Mouraviev V, Robertson CN, Albala DM, Moul JW. Tumor percent involvement predicts prostate specific antigen recurrence after radical prostatectomy only in men with smaller prostate. J Urol. 2010 Mar;183(3):997-1001. (2010)
• Bañez LL, Blake GW, McLeod DG, Crawford ED, Moul JW. Combined low-dose flutamide plus finasteride vs low-dose flutamide monotherapy for recurrent prostate cancer: a comparative analysis of two phase II trials with a long-term follow-up. BJU Int. 2009 Aug;104(3):310-4. (2009)
• Bañez LL, Sun L, Trock BJ, Han M, Partin AW, Aronson WJ, Terris MK, Presti JC Jr, Kane CJ, Amling CL, Moul JW, Freedland SJ. Body mass index and prostate specific antigen as predictors of adverse pathology and biochemical recurrence after prostatectomy. J Urol. 2009 Aug;182(2):491-6; discussion 496-8. (2009)
• Caire AA, Sun L, Ode O, Stackhouse DA, Maloney K, Donatucci C, Mouraviev V, Polascik TJ, Robertson CN, Albala DM, Moul JW. Delayed prostate-specific antigen recurrence after radical prostatectomy: how to identify and what are their clinical outcomes? Urology. 2009 Sep;74(3):643-7. (2009)
• Caire AA, Sun L, Robertson CN, Polascik TJ, Maloney KE, George DJ, Price MM, Stackhouse DA, Lack BD, Albala DM, Moul JW. Public Survey and Survival Data Do Not Support Recommendations to Discontinue Prostate-specific Antigen Screening in Men at Age 75. Urology. 2009 Oct 6. (2009)
• Chen VH, Mouraviev V, Mayes JM, Sun L, Madden JF, Moul JW, Polascik TJ. Utility of a 3-dimensional transrectal ultrasound-guided prostate biopsy system for prostate cancer detection. Technol Cancer Res Treat. 2009 Apr;8(2):99-104. (2009)
• Chino J, Schroeck FR, Sun L, Lee WR, Albala DM, Moul JW, Koontz BF. Robot-assisted laparoscopic prostatectomy is not associated with early postoperative radiation therapy. BJU Int. 2009 Nov;104(10):1496-500. (2009)
• D'Alonzo RC, Gan TJ, Moul JW, Albala DM, Polascik TJ, Robertson CN, Sun L, Dahm P, Habib AS. A retrospective comparison of anesthetic management of robot-assisted laparoscopic radical prostatectomy versus radical retropubic prostatectomy. J Clin Anesth. 2009 Aug;21(5):322-8. (2009)
• Droz JP, Balducci L, Bolla M, Emberton M, Fitzpatrick JM, Joniau S, Kattan MW, Monfardini S, Moul JW, Naeim A, van Poppel H, Saad F, Sternberg CN. Background for the proposal of SIOG guidelines for the management of prostate cancer in senior adults. Crit Rev Oncol Hematol. 2009 Oct 15. (2009)
• Freedland SJ, Bañez LL, Sun LL, Fitzsimons NJ, Moul JW. Obese men have higher-grade and larger tumors: an analysis of the duke prostate center database. Prostate Cancer Prostatic Dis. 2009;12(3):259-63. (2009)
• Habib AS, Polascik TJ, Weizer AZ, White WD, Moul JW, ElGasim MA, Gan TJ. Lidocaine patch for postoperative analgesia after radical retropubic prostatectomy. Anesth Analg. 2009 Jun;108(6):1950-3. (2009)
• Jayachandran J, Schroeck F, Sun L, Gerber L, Moreira DM, Moul JW, Freedland SJ. The Shared Equal Access Regional Cancer Hospital (SEARCH) nomogram for risk stratification in intermediate risk group of men with prostate cancer: validation in the Duke Prostate Center database. BJU Int. 2009 Aug 25. (2009)
• Moul JW, Mouraviev V, Sun L, Schroeck FR, Polascik TJ. Prostate cancer: the new landscape. Curr Opin Urol. 2009 Mar;19(2):154-60. (2009)
• Moul JW, Tang P, Sun L. Editorial Comment on: Development of a New Method for Monitoring Prostate-Specific Antigen Changes in Men with Localised Prostate Cancer: A Comparison of Observational Cohorts. Eur Urol. 2009 Mar 13. (2009)
• Moul JW. Innovations in urology from military medicine. Urol Oncol. 2009 Sep-Oct;27(5):551-2. (2009)
• Moul JW. Post-radical prostatectomy management options for positive surgical margins: argument for observation. Urol Oncol. 2009 Jan-Feb;27(1):92-6. (2009)
• Moul JW. Report from Durham. Prostate Cancer Prostatic Dis. 2009;12(3):209-10. (2009)
• Moul JW. Twenty years of controversy surrounding combined androgen blockade for advanced prostate cancer. Cancer. 2009 Aug 1;115(15):3376-8. (2009)
• Moul JW. Twenty-five year evolution of medical hormonal therapy for prostate cancer. BJU Int. 2009 Jan;103(2):145-6. (2009)
• Moul JW. Will the global economic downturn affect prostate cancer care? Pelvic lymphadenectomy as an example. Eur Urol. 2009 Jun;55(6):1266-8. (2009)
• Nguyen PL, Chen MH, Catalona WJ, Moul JW, Sun L, D'Amico AV. Predicting prostate cancer mortality among men with intermediate to high-risk disease and multiple unfavorable risk factors. Int J Radiat Oncol Biol Phys. 2009 Mar 1;73(3):659-64. (2009)
• Polascik TJ, Mayes JM, Schroeck FR, Sun L, Madden JF, Moul JW, Mouraviev V. Patient selection for hemiablative focal therapy of prostate cancer: variables predictive of tumor unilaterality based upon radical prostatectomy. Cancer. 2009 May 15;115(10):2104-10. (2009)
• Stackhouse DA, Sun L, Schroeck FR, Jayachandran J, Caire AA, Acholo CO, Robertson CN, Albala DM, Polascik TJ, Donatucci CF, Maloney KE, Moul JW. Factors predicting prostatic biopsy Gleason sum under grading. J Urol. 2009 Jul;182(1):118-22; discussion 123-4. (2009)
• Sun L, Caire AA, Robertson CN, George DJ, Polascik TJ, Maloney KE, Walther PJ, Stackhouse DA, Lack BD, Albala DM, Moul JW. Men older than 70 years have higher risk prostate cancer and poorer survival in the early and late prostate specific antigen eras. J Urol. 2009 Nov;182(5):2242-8. (2009)
• Tsivian M, Sun L, Mouraviev V, Madden JF, Mayes JM, Moul JW, Polascik TJ. Changes in Gleason score grading and their effect in predicting outcome after radical prostatectomy. Urology. 2009 Nov;74(5):1090-3. (2009)
• Uhlman MA, Sun L, Stackhouse DA, Caire AA, Polascik TJ, Robertson CN, Madden J, Vollmer R, Albala DM, Moul JW. Tumor Volume, Tumor Percentage Involvement, or Prostate Volume: Which Is Predictive of Prostate-specific Antigen Recurrence? Urology. 2009 Oct 10. (2009)
• Xu DD, Sun SD, Wang F, Sun L, Stackhouse D, Polascik T, Albala DM, Moul JW, Caire A, Robertson CN. Effect of age and pathologic Gleason score on PSA recurrence: analysis of 2911 patients undergoing radical prostatectomy. Urology. 2009 Sep;74(3):654-8. (2009)